Spots Global Cancer Trial Database for surufatinib
Every month we try and update this database with for surufatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | NCT04169672 | Advanced Solid ... | Surufatinib Toripalimab | 18 Years - 75 Years | Hutchmed | |
| Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | NCT05595889 | Small Cell Lung... Angiogenesis Chemotherapy Ef... | Surufatinib Irinotecan | 18 Years - 80 Years | Fujian Cancer Hospital | |
| Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study | NCT04764006 | Advanced Colore... | Surufatinib | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors | NCT05527821 | Unresectable Ad... Biliary Tract T... | Surufatinib Sintilimab Short course ra... | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | NCT06158516 | Pancreatic Neur... | Surufatinib Placebo | 18 Years - 75 Years | Changhai Hospital | |
| Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | NCT04653480 | Colorectal Canc... | Surufatinib Toripalimab chemotherapy | 18 Years - 75 Years | Zhejiang University | |
| Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer | NCT06255262 | Biliary Tract C... | Surufatinib Durvalumab | 18 Years - | China Medical University, China | |
| Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples | NCT05171439 | Hepatocellular ... | Surufatinib | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas | NCT05013515 | Salivary Gland ... | Surufatinib | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Surufatinib in G3 Neuroendocrine Tumors | NCT05973968 | Neuroendocrine ... | Surufatinib | 18 Years - | Qilu Hospital of Shandong University | |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | NCT06134193 | Carcinoma Intrahepatic Ch... Gallbladder Can... Surufatinib Angiogenesis In... Tislelizumab Antineoplastic ... Immunotherapy | HAIC Surufatinib Tislelizumab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC | NCT05165407 | Neuroendocrine ... | Sintilimab IBI310 Surufatinib | 18 Years - 75 Years | Peking University | |
| Surufatinib in G3 Neuroendocrine Tumors | NCT05973968 | Neuroendocrine ... | Surufatinib | 18 Years - | Qilu Hospital of Shandong University | |
| Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma | NCT05106777 | Sarcoma | Surufatinib | 14 Years - 70 Years | Sun Yat-sen University | |
| Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma | NCT06102746 | Gastric Neuroen... | Sintilimab，Suru... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | NCT05494580 | Ovarian Cancer Ovarian Carcino... Platinum-resist... Fallopian Tube ... Primary Periton... | Pamiparib Surufatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | NCT05652283 | Ovarian Cancer | Pamiparib Surufatinib | 18 Years - | Anhui Provincial Cancer Hospital | |
| A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma | NCT06110650 | Soft Tissue Sar... | Surufatinib | 18 Years - | Fudan University | |
| Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas | NCT05013515 | Salivary Gland ... | Surufatinib | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | NCT05472948 | Adenocarcinoma ... Appendix Carcin... Metastatic | Surufatinib Sintilimab Capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | NCT05595889 | Small Cell Lung... Angiogenesis Chemotherapy Ef... | Surufatinib Irinotecan | 18 Years - 80 Years | Fujian Cancer Hospital | |
| Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma | NCT06102746 | Gastric Neuroen... | Sintilimab，Suru... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | NCT05746728 | Metastatic Trip... | Surufatinib Tislelizumab | 18 Years - | Tongji Hospital | |
| Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation | NCT06414915 | NSCLC | Surufatinib Tislelizumab | 18 Years - 75 Years | National Cancer Center, China | |
| Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | NCT04169672 | Advanced Solid ... | Surufatinib Toripalimab | 18 Years - 75 Years | Hutchmed | |
| Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | NCT06361030 | Pancreatic Canc... Pancreatic Canc... Pancreatic Duct... | surufatinib com... | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | NCT02966821 | Biliary Tract C... | Surufatinib | 18 Years - | Hutchmed | |
| An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors | NCT06038461 | Neuroendocrine ... | Surufatinib Com... | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | NCT05746728 | Metastatic Trip... | Surufatinib Tislelizumab | 18 Years - | Tongji Hospital | |
| Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | NCT02588170 | Neuroendocrine ... | Surufatinib Placebo | 18 Years - | Hutchmed | |
| Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | NCT04653480 | Colorectal Canc... | Surufatinib Toripalimab chemotherapy | 18 Years - 75 Years | Zhejiang University | |
| Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer | NCT04922658 | Advanced Non-Sm... | Surufatinib Surufatinib Plu... | 18 Years - 80 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | |
| Open-Label Surufatinib in European Patients With NET | NCT04579679 | Neuroendocrine ... Neuroendocrine ... Small Intestina... | Surufatinib | 18 Years - | Hutchmed | |
| Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | NCT06361030 | Pancreatic Canc... Pancreatic Canc... Pancreatic Duct... | surufatinib com... | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | NCT05627427 | Neuroendocrine ... Neuroendocrine ... Pancreatic Carc... | Surufatinib Sintilimab | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma | NCT05839275 | High-Risk Local... | Surufatinib Sintilimab Radiotherapy | 18 Years - 70 Years | Fudan University | |
| Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer | NCT05989425 | Differentiated ... | surufatinib | 18 Years - 75 Years | Fudan University | |
| Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma | NCT06102746 | Gastric Neuroen... | Sintilimab，Suru... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | NCT06158516 | Pancreatic Neur... | Surufatinib Placebo | 18 Years - 75 Years | Changhai Hospital | |
| A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC | NCT05236699 | Intrahepatic Ch... | DEB-TACE combin... | 18 Years - 75 Years | Tongji Hospital | |
| Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer | NCT04922658 | Advanced Non-Sm... | Surufatinib Surufatinib Plu... | 18 Years - 80 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | |
| Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer | NCT05989425 | Differentiated ... | surufatinib | 18 Years - 75 Years | Fudan University | |
| Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | NCT02588170 | Neuroendocrine ... | Surufatinib Placebo | 18 Years - | Hutchmed | |
| Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer | NCT05832892 | Unresectable Lo... | surufatinib KN046 gemcitabine Nab paclitaxel | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma | NCT05064852 | Biliary Tract C... | Surufatinib | 18 Years - | Qilu Hospital of Shandong University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
